002750.SZ
Kunming Longjin Pharmaceutical Co., Ltd. [002750.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002750.SZ Stock Summary
Top 10 Correlated Stocks
002750.SZ
In the News
002750.SZ Financial details
Company Rating
Buy
Market Cap
4.14B
Income
-93.03M
Revenue
91.24M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
262
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
-44.47
Forward P/E
-
PEG
-0.45
P/S
45.39
P/B
7.44
P/C
-
P/FCF
-45.01
Quick Ratio
6.25
Current Ratio
6.84
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-0.2
EPS next Y
-
EPS next Q
-
EPS this Y
867.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-18.21%
Revenue Q/Q
24.18%
EPS Q/Q
-
-
-
-
-
SMA20
-5.08%
SMA50
0.74%
SMA100
17.59%
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-16%
ROC
-0.13%
Gross Margin
68%
Oper. Margin
-90%
Profit Margin
-102%
Payout
-
Shs Outstand
400.5M
Shs Float
164.07M
-
-
-
-
Target Price
-
52W Range
8.8-16.0
52W High
-35.38%
52W Low
+29.25%
RSI
40.09
Rel Volume
0.32
Avg Volume
20.49M
Volume
6.48M
Perf Week
-5.74%
Perf Month
-0.19%
Perf Quarter
13.13%
Perf Half Y
10%
-
-
-
-
Beta
0.242
-
-
Volatility
0.24%, 0.41%
Prev Close
-1.34%
Price
10.34
Change
-3.27%
002750.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.84 | 0.69 | 0.63 | 1.75 | 0.31 | |
| Net income per share | 0.03 | -0.06 | 0.02 | -0.02 | -0.18 | |
| Operating cash flow per share | 0.08 | 0.01 | -0.02 | -0.04 | -0.04 | |
| Free cash flow per share | 0.04 | -0.01 | -0.08 | -0.06 | -0.1 | |
| Cash per share | 0.95 | 1.01 | 1.03 | 1.07 | 1.01 | |
| Book value per share | 1.61 | 1.56 | 1.59 | 1.59 | 1.46 | |
| Tangible book value per share | 1.56 | 1.53 | 1.64 | 1.57 | 1.4 | |
| Share holders equity per share | 1.61 | 1.56 | 1.59 | 1.59 | 1.46 | |
| Interest debt per share | 0.03 | 0 | 0 | 0 | 0.04 | |
| Market cap | 2.24B | 5.15B | 3.36B | 6.48B | 4.46B | |
| Enterprise value | 1.86B | 4.96B | 3.23B | 6.38B | 4.27B | |
| P/E ratio | 161.85 | -215.32 | 432.7 | -868.62 | -60.63 | |
| Price to sales ratio | 6.68 | 18.72 | 13.21 | 9.22 | 36.25 | |
| POCF ratio | 70.82 | 1.27K | -495.11 | -437.72 | -308.67 | |
| PFCF ratio | 138.85 | -1.7K | -110.42 | -257.6 | -112.4 | |
| P/B Ratio | 3.47 | 8.26 | 5.28 | 10.14 | 7.65 | |
| PTB ratio | 3.47 | 8.26 | 5.28 | 10.14 | 7.65 | |
| EV to sales | 5.54 | 18.01 | 12.72 | 9.08 | 34.71 | |
| Enterprise value over EBITDA | 69.71 | 80.9 | 85.87 | 168.9 | -511.21 | |
| EV to operating cash flow | 58.7 | 1.23K | -476.81 | -430.92 | -295.52 | |
| EV to free cash flow | 115.08 | -1.64K | -106.34 | -253.6 | -107.61 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | -0.02 | |
| Free cash flow yield | 0.01 | 0 | -0.01 | 0 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -14.4 | -3.19 | -3.29 | -2.67 | 22.75 | |
| Current ratio | 4.75 | 4.56 | 5.18 | 4.61 | 5.37 | |
| Interest coverage | 1.62 | 0 | 0 | 14.79 | -2.59 | |
| Income quality | 2.29 | -0.17 | -0.87 | 1.98 | 0.2 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.87 | 0 | 0 | -0.05 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.01 | 0.07 | |
| Research and developement to revenue | 0.1 | 0.08 | 0.08 | 0.03 | 0.2 | |
| Intangibles to total assets | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Capex to operating cash flow | -0.49 | -1.75 | 3.48 | 0.7 | 1.75 | |
| Capex to revenue | -0.05 | -0.03 | -0.09 | -0.01 | -0.21 | |
| Capex to depreciation | -0.68 | -0.27 | -0.84 | -0.34 | -0.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.12 | 1.45 | 0.83 | 0.82 | 2.45 | |
| ROIC | 0.02 | 0.06 | 0.01 | 0.01 | -0.06 | |
| Return on tangible assets | 0.02 | -0.03 | 0.01 | -0.01 | -0.1 | |
| Graham Net | 0.75 | 0.77 | 0.84 | 0.84 | 0.75 | |
| Working capital | 373.13M | 374.23M | 419.33M | 409.37M | 383.38M | |
| Tangible asset value | 624.91M | 613.72M | 655.95M | 629.21M | 559.77M | |
| Net current asset value | 340.95M | 338.48M | 382.56M | 373.78M | 328.6M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 50.55M | 42.93M | 42.59M | 52.32M | 45.92M | |
| Average payables | 10.88M | 14.49M | 14.63M | 13.55M | 10.96M | |
| Average inventory | 28.53M | 31.45M | 45.19M | 43.79M | 30.34M | |
| Days sales outstanding | 52.85 | 49.34 | 68.91 | 29.45 | 104.38 | |
| Days payables outstanding | 164.98 | 105.8 | 108.6 | 8.91 | 144.21 | |
| Days of inventory on hand | 299.36 | 270.1 | 388.61 | 24.8 | 396.52 | |
| Receivables turnover | 6.91 | 7.4 | 5.3 | 12.4 | 3.5 | |
| Payables turnover | 2.21 | 3.45 | 3.36 | 40.95 | 2.53 | |
| Inventory turnover | 1.22 | 1.35 | 0.94 | 14.72 | 0.92 | |
| ROE | 0.02 | -0.04 | 0.01 | -0.01 | -0.13 | |
| Capex per share | -0.04 | -0.02 | -0.06 | -0.03 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.05 | 0.05 | 0.06 | 0 | |
| Net income per share | -0.01 | -0.16 | -0.02 | -0.02 | 0 | |
| Operating cash flow per share | -0.01 | -0.16 | -0.02 | 0 | 0 | |
| Free cash flow per share | -0.04 | -0.18 | -0.03 | -0.01 | 0 | |
| Cash per share | 1.05 | 1.01 | 0.89 | 0.88 | 0 | |
| Book value per share | 1.6 | 1.46 | 1.44 | 1.42 | 0 | |
| Tangible book value per share | 1.57 | 1.4 | 1.36 | 1.29 | 0 | |
| Share holders equity per share | 1.6 | 1.46 | 1.44 | 1.42 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 3.94B | 4.46B | 4.27B | 3.71B | 0 | |
| Enterprise value | 3.86B | 4.27B | 4.12B | 3.61B | -92.03M | |
| P/E ratio | -248.31 | -17.12 | -113.29 | -120.97 | 0 | |
| Price to sales ratio | 159.54 | 220.85 | 197.95 | 167.88 | 0 | |
| POCF ratio | -993.25 | -68.49 | -453.18 | 0 | 0 | |
| PFCF ratio | -233.54 | -63.24 | -311.27 | -661.75 | 0 | |
| P/B Ratio | 6.19 | 7.65 | 7.42 | 6.53 | 0 | |
| PTB ratio | 6.19 | 7.65 | 7.42 | 6.53 | 0 | |
| EV to sales | 156.34 | 211.44 | 191.34 | 163.46 | -3.36 | |
| Enterprise value over EBITDA | -324.16 | -181.82 | -425.25 | -448.2 | 5.03 | |
| EV to operating cash flow | -973.34 | -65.57 | -438.05 | 0 | 0 | |
| EV to free cash flow | -228.86 | -60.54 | -300.88 | -644.34 | 41.76 | |
| Earnings yield | 0 | -0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | -0.02 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 6.63 | 8.09 | 14.68 | 12.11 | 5.03 | |
| Current ratio | 5.05 | 5.37 | 8.52 | 6.76 | 6.84 | |
| Interest coverage | -25.72 | -1.11K | 6.44 | 0 | 0 | |
| Income quality | 1 | 1 | 1 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.64 | -0.54 | 0.32 | -0.06 | 0.65 | |
| Research and developement to revenue | 0.19 | 0.49 | 0.19 | 0.18 | 0.17 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.07 | 0.11 | 0.11 | |
| Capex to operating cash flow | 3.25 | 0.08 | 0.46 | 0 | 0 | |
| Capex to revenue | -0.52 | -0.27 | -0.2 | -0.25 | -0.08 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.6 | 2.31 | 0.87 | 0.78 | 0 | |
| ROIC | -0.01 | -0.09 | -0.02 | -0.02 | -0.02 | |
| Return on tangible assets | -0.01 | -0.09 | -0.01 | -0.01 | -0.02 | |
| Graham Net | 0.85 | 0.75 | 0.75 | 0.71 | 0 | |
| Working capital | 404.03M | 383.38M | 364.67M | 353.2M | 351.42M | |
| Tangible asset value | 620.47M | 559.77M | 544.57M | 516.44M | 504.99M | |
| Net current asset value | 370.65M | 328.6M | 322.63M | 311.8M | 310.66M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 47.62M | 37.23M | 28.44M | 23.9M | 27.48M | |
| Average payables | 13.33M | 11.07M | 10.24M | 11.72M | 11.96M | |
| Average inventory | 44.22M | 36.96M | 29.14M | 31.65M | 32.02M | |
| Days sales outstanding | 143.37 | 156.78 | 90.65 | 106.37 | 94.75 | |
| Days payables outstanding | 238.27 | 123.34 | 139.33 | 180.5 | 109.59 | |
| Days of inventory on hand | 913.74 | 339.13 | 409.28 | 453.43 | 315.2 | |
| Receivables turnover | 0.63 | 0.57 | 0.99 | 0.85 | 0.95 | |
| Payables turnover | 0.38 | 0.73 | 0.65 | 0.5 | 0.82 | |
| Inventory turnover | 0.1 | 0.27 | 0.22 | 0.2 | 0.29 | |
| ROE | -0.01 | -0.11 | -0.02 | -0.01 | -0.02 | |
| Capex per share | -0.03 | -0.01 | -0.01 | -0.01 | 0 |
002750.SZ Frequently Asked Questions
What is Kunming Longjin Pharmaceutical Co., Ltd. stock symbol ?
Kunming Longjin Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002750.SZ
What is Kunming Longjin Pharmaceutical Co., Ltd. stock quote today ?
Kunming Longjin Pharmaceutical Co., Ltd. stock price is $10.34 today.
Is Kunming Longjin Pharmaceutical Co., Ltd. stock public?
Yes, Kunming Longjin Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 20.49M
- Market Capitalization 4.14B
- Employee 262
- CEO Ms. Yan Li Fan
- Headquarters Kunming,CN
- IPO Date 2015-03-24
-
Website
https://www.longjin.com.cn 
Kunmig Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. The company offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. It also engages in the industrial hemp plantation business. The company was founded in 1996 and is headquartered in Kunming, China.
